Literature DB >> 25220102

Recurrent vulvovaginitis.

Anna M Powell1, Paul Nyirjesy2.   

Abstract

Vulvovaginitis (VV) is one of the most commonly encountered problems by a gynecologist. Many women frequently self-treat with over-the-counter medications, and may present to their health-care provider after a treatment failure. Vulvovaginal candidiasis, bacterial vaginosis, and trichomoniasis may occur as discreet or recurrent episodes, and have been associated with significant treatment cost and morbidity. We present an update on diagnostic capabilities and treatment modalities that address recurrent and refractory episodes of VV.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  bacterial vaginosis; trichomoniasis; vaginitis; vulvaginal candidiasis

Mesh:

Year:  2014        PMID: 25220102     DOI: 10.1016/j.bpobgyn.2014.07.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Obstet Gynaecol        ISSN: 1521-6934            Impact factor:   5.237


  10 in total

1.  Real-world effectiveness and tolerability of Zelesse cream® for treating vulvovaginitis in adult women: an observational, prospective study.

Authors:  Ana Rosa Masero; Luís Manuel San Frutos; Ernesto Vizcaíno; María Palma; Syra Velasco-Ortega; Concepción Nieto
Journal:  J Int Med Res       Date:  2021-05       Impact factor: 1.671

2.  Genetic and Phenotypic Screening of Mannose-Binding Lectin in Relation to Risk of Recurrent Vulvovaginal Infections in Women of North India: A Prospective Cohort Study.

Authors:  Namarta Kalia; Jatinder Singh; Sujata Sharma; Hardesh Arora; Manpreet Kaur
Journal:  Front Microbiol       Date:  2017-01-31       Impact factor: 5.640

3.  Is uncertain vulvovaginal candidiasis a marker of vulvodynia? A study in a Dutch general practice research database.

Authors:  Peter Leusink; Daphne van Moorsel; Hans Bor; Gé A Donker; Peter Lucassen; Doreth Teunissen; Ellen Laan; Antoine Lagro-Janssen
Journal:  BJGP Open       Date:  2017-05-31

4.  Efficacy, acceptability and tolerability of Zelesse® for the treatment of non-specific vulvovaginitis in paediatric patients: The NINESSE Study.

Authors:  Fátima García; Carmen-Amparo Rodríguez; María-Lourdes Palomo; Pere Català; Santiago Fernández; Ibone Huerta; Syra Velasco; Concepción Nieto
Journal:  J Int Med Res       Date:  2018-06-07       Impact factor: 1.671

Review 5.  Immunopathology of Recurrent Vulvovaginal Infections: New Aspects and Research Directions.

Authors:  Namarta Kalia; Jatinder Singh; Manpreet Kaur
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

Review 6.  Microbiota in vaginal health and pathogenesis of recurrent vulvovaginal infections: a critical review.

Authors:  Namarta Kalia; Jatinder Singh; Manpreet Kaur
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-01-28       Impact factor: 3.944

7.  High incidence of azole resistance among Candida albicans and C. glabrata isolates in Northeastern Iran.

Authors:  Hossein Zarrinfar; Zahra Kord; Abdolmajid Fata
Journal:  Curr Med Mycol       Date:  2021-09

Review 8.  Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review.

Authors:  Werner Mendling; Ernst Rainer Weissenbacher; Stefan Gerber; Valdas Prasauskas; Philipp Grob
Journal:  Arch Gynecol Obstet       Date:  2015-10-27       Impact factor: 2.344

9.  A Comprehensive in Silico Analysis of Regulatory SNPs of Human CLEC7A Gene and Its Validation as Genotypic and Phenotypic Disease Marker in Recurrent Vulvovaginal Infections.

Authors:  Namarta Kalia; Manpreet Kaur; Sujata Sharma; Jatinder Singh
Journal:  Front Cell Infect Microbiol       Date:  2018-03-20       Impact factor: 5.293

10.  Improving the Diagnosis of Vulvovaginitis: Perspectives to Align Practice, Guidelines, and Awareness.

Authors:  Haywood Brown; Madeline Drexler
Journal:  Popul Health Manag       Date:  2020-10       Impact factor: 2.459

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.